New shareholder – Medifarma Group

Founded in 1947 Laboratorios Atral entered in a new life cycle, after being acquired in September of 2016 by Medifarma S.A. 

Medifarma produces a wide range of pharmaceutical ethical products, generics and OTC´s, being the leader in the pharmaceutical Peruvian market.

Following recent investments in Uruguay and Brazil, the Medifarma Group starts its presence in Europe after the acquisition of Atral with the objective to expand its activities in Europe, Africa, Middle East and the Far East. Atral will also be able to consolidate its presence in traditional markets in Central America and the Caribbean.

With differentiating industrial competences in Portugal, in the area of Penicillin’s and Cephalosporin’s, Atral integrates the international strategy of Medifarma Group from 2016 and will have its capabilities expanded, namely in what is its “DNA”, the Antibiotics.

In commercial terms, the Group’s objectives for Atral includes expansion of exports, diversification of products and markets, and in the domestic market by extension of the product line, maximizing the synergies between the various units of the Group.

read online

Photography: Maria João Gala (image taken from the newspaper Público online)